Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

American Eagle Outfitters targets mid-single-digit comp sales growth and $390M–$410M operating profit in 2026 while expanding Aerie and OFFLINE

View original at seekingalpha.com
American Eagle Outfitters targets mid-single-digit comp sales growth and $390M–$410M operating profit in 2026 while expanding Aerie and OFFLINE Earnings Call Insights: American Eagle Outfitters (AEO) Q4 2025 MANAGEMENT VIEW * Jay Schottenstein, Executive Chairman and CEO, credited a "deliberate action plan" for ignitin…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Gross margin expected in mid to high 30% range in Q1 2026, lower in Q2, with improvement in second half as tariffs are cycled

    80% confidence

  • Commitment to product leadership continues to be a key engine driving business

    80% confidence

  • Company exited Q4 2025 with record brand awareness and double-digit customer acquisition

    80% confidence

  • Planning at least 60 store remodels in 2026, with remodeled stores outperforming chain average

    80% confidence

  • Expected annual savings of $20 million from Quiet Logistics exit and corporate restructuring

    80% confidence

  • Intimates saw great success in Q4 and continuing that momentum into Q1

    80% confidence

  • Planning 35-40 openings for Aerie and OFFLINE in 2026 and 25-35 net closings for American Eagle

    80% confidence

  • Expect some pressure in denim but also getting into new categories that are trending

    80% confidence

  • Deliberate action plan ignited growth, improved profitability, and fueled strong finish to 2025

    80% confidence

  • OFFLINE had steady sales in active bottoms and double-digit growth in sports bras, tops and fashion bottoms

    80% confidence

  • All categories really worked at Aerie with continued momentum into Q1

    80% confidence

  • Aerie strength has been broad-based across all categories

    80% confidence

  • Aerie and OFFLINE delivered 23% comp growth with broad-based demand

    80% confidence

  • No specific intent around tariff pass-through pricing

    80% confidence

  • Q1 2026 comparable sales expected to grow in high single digits, with American Eagle in positive low single digits and Aerie OFFLINE in double digits

    80% confidence

  • Full-year 2026 operating profit expected in range of $390M to $410M based on mid-single digit comparable sales growth

    80% confidence

  • 80% of annual operating profit expected to be generated in second half of 2026 due to tariff and advertising spend timing

    80% confidence

  • Strong performance in Q4 is testament to work with results coming in ahead of expectations across margins and profitability

    80% confidence

  • Confident that we have only just begun to scratch the surface of this brand's massive and long-term potential

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
American Eagle Outfitters targets mid-single-digit comp sales growth and $390M–$410M operating profit in 2026 while expanding Aerie and OFFLINE — Source | Via News | ViaNews EU